NASDAQ
17.59USD
0.00 (0.00%)
We have scored 15 news catalysts on Zealand Pharma A/S (ZEAL) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.27). Most of the impact sits in forward growth expectations and price momentum.
Market cap
0
P/E
—
EPS
—
Beta
1.34
52W range
—
Day range
17.47–18.07
Open
18.03
Prev close
17.59
Volume
2.2K
Avg volume
1.6K
Dividend
0.00
IPO
2017-08-09
No scored news tagged ZEAL or its network in the window yet.
Show more ZEAL articles →Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zealand Pharma A/S — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ZEAL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works